Axsome Therapeutics’ (AXSM) “Overweight” Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Monday, Benzinga reports. The brokerage currently has a $107.00 price target on the stock. Several other research firms also recently issued reports on AXSM. Bank of America raised Axsome Therapeutics from a neutral rating to […]
19 Sep 06:00 · The Markets Daily